Effect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides
Randomized Clinical Trial

Angela J. Hanson, MD; Jennifer L. Bayer-Carter, PhD; Pattie S. Green, PhD; Thomas J. Montine, MD, PhD; Charles W. Wilkinson, PhD; Laura D. Baker, PhD; G. Stennis Watson, PhD; Laura M. Bonner, PhD; Maureen Callaghan, MD; James B. Leverenz, MD; Elaine Tsai, MD; Nadia Postupna, PhD; Jing Zhang, PhD; Johanna Lamp, PhD; Suzanne Craft, PhD

IMPORTANCE Sporadic Alzheimer disease (AD) is caused in part by decreased clearance of the β-amyloid (Aβ) peptide breakdown products. Lipid-depleted (LD) apolipoproteins are less effective at binding and clearing Aβ, and LD Aβ peptides are more toxic to neurons. However, not much is known about the lipid states of these proteins in human cerebrospinal fluid.

OBJECTIVE To characterize the lipidation states of Aβ peptides and apolipoprotein E in the cerebrospinal fluid in adults with respect to cognitive diagnosis and APOE ε4 allele carrier status and after a dietary intervention.

DESIGN Randomized clinical trial.

SETTING Veterans Affairs Medical Center clinical research unit.


INTERVENTIONS Randomization to a diet high in saturated fat content and with a high glycemic index (High diet; 45% of energy from fat [>25% saturated fat], 35%-40% from carbohydrates with a mean glycemic index >70, and 15%-20% from protein) or a diet low in saturated fat content and with a low glycemic index (Low diet; 25% of energy from fat [<7% saturated fat], 55%-60% from carbohydrates with a mean glycemic index <55, and 15%-20% from protein).

MAIN OUTCOMES AND MEASURES Lipid-depleted Aβ42 and Aβ40 and apolipoprotein E in cerebrospinal fluid.

RESULTS Baseline levels of LD Aβ were greater for adults with mild cognitive impairment compared with adults with normal cognition (LD Aβ42, P = .05; LD Aβ40, P = .01). These findings were magnified in adults with mild cognitive impairment and the e4 allele, who had higher LD apolipoprotein E levels irrespective of cognitive diagnosis (P < .001). The Low diet tended to decrease LD Aβ levels, whereas the High diet increased these fractions (LD Aβ42, P = .01; LD Aβ40, P = .15). Changes in LD Aβ levels with the Low diet negatively correlated with changes in cerebrospinal fluid levels of insulin (LD Aβ42 and insulin, r = −0.68 [P = .01]; LD Aβ40 and insulin, r = −0.78 [P = .002]).

CONCLUSIONS AND RELEVANCE The lipidation states of apolipoproteins and Aβ peptides in the brain differ depending on APOE genotype and cognitive diagnosis. Concentrations can be modulated by diet. These findings may provide insight into the mechanisms through which apolipoprotein E4 and unhealthy diets impart risk for developing AD.
Sporadic Alzheimer disease (AD) is caused in part by accumulation of β-amyloid (Aβ) peptides in the brain. These peptides can be bound to lipids or to lipid carrier proteins, such as apolipoprotein E (ApoE), or be free in solution (lipid-depleted [LD] Aβ). Levels of LD Aβ are higher in the plasma of adults with AD, but less is known about these peptides in the cerebrospinal fluid (CSF). Understanding the lipid environment in which Aβ exists—and understanding how to modulate that environment—is of interest because LD Aβ is more likely to form neurotoxic oligomers.

One mechanism that could affect Aβ lipidation is to alter the concentration or function of the Aβ-binding apolipoproteins. Different alleles of APOE influence AD risk, with presence of an ε4 allele as a risk for AD (herein referred to as E4+ if present and E4− if absent), whereas the ε2 allele is protective. Adults with E4+ status have higher levels of brain amyloid, suggesting that the ApoE protein plays a role in Aβ clearance.

Studies in cell culture and animals have shown that the function of ApoE depends on the degree to which it is associated with lipids (lipidation state) and that the ApoE4 isoform is less lipidated and less able to bind and clear Aβ. Little is known about LD ApoE in human CSF.

Another way to alter Aβ lipidation is through diet. Diets high in levels of saturated fat, cholesterol, and simple sugars have been implicated in AD pathogenesis and increase brain amyloid chemistry in animal models. Disrupted brain insulin signaling is thought to be one mechanism for how these diets affect the central nervous system because insulin may be involved in clearing Aβ. In a previously published diet intervention, we showed that a diet high in saturated fat content and with a high glycemic index (High diet) worsened CSF biomarkers of AD, lowered CSF insulin levels, and worsened visual memory, whereas a diet low in saturated fat content and with a low glycemic index (Low diet) had opposing effects. In our pilot study, we examine changes in LD ApoE and LD Aβ levels in the CSF of older adults at baseline and after diet intervention.

Herein we provide preliminary evidence that E4+ adults have higher basal levels of LD ApoE and that adults with mild cognitive impairment (MCI), particularly E4+ adults, have higher levels of LD Aβ. We also show that a High diet increases LD Aβ levels and that a Low diet has opposing effects. Furthermore, diet-induced changes in LD Aβ levels inversely correlate with changes in CSF insulin levels. These findings may provide insight into the mechanisms through which ApoE4 and unhealthy diets impart risk for developing AD.

Methods

Study Participants

Study methods were published previously in detail. This study was approved by the human subjects review committees of the University of Washington and the Veterans Affairs Puget Sound Health Care System. Written informed consent was obtained from all participants. All participants underwent a comprehensive neuropsychological battery. Participants with a delayed memory score of no more than 1.5 SDs from an estimate of their premorbid ability were considered for the diagnosis of amnestic MCI by expert consensus as per published criteria. Participants were excluded from the study if they had major psychiatric or neurologic disorders, alcoholism, renal or hepatic disease, diabetes mellitus, chronic obstructive pulmonary disease, unstable cardiac disease, or hyperlipidemia requiring cholesterol-lowering medication, including statins, fibrates, niacin, and fish oil. Each participant also underwent APOE genotyping.

Intervention

Study participants were randomized to receive the High or Low diet for 4 weeks. Participants and personnel involved in data collection were blinded to treatment. Blood and CSF samples were collected at baseline and week 4. The High diet provided 45% energy from total fat (25% from saturated fat), 35% to 40% from carbohydrates with a glycemic index greater than 70, and 15% to 20% from protein. The Low diet consisted of 25% energy from fat (<7% from saturated fat), 55% to 60% from carbohydrates with a glycemic index less than 55, and 15% to 20% from protein. Menus were created by a research nutritionist (J.L.B.-C.) using commercially available software (ProNutra; VioCare Inc) to ensure adherence to macronutrient targets, and energy needs were calculated by averaging the Mifflin-St Jeor and Harris-Benedict equations as previously described. Diets were isocaloric, and weight remained stable for both diet groups. The glycemic index was calculated as described elsewhere. Adherence was assessed by having participants keep daily food records, and the number of nonadherent incidents (including failure to eat an entire item or eating an extra item) was small and comparable between diets (mean number of incidents per week, 1.49 for the Low diet vs 1.25 for the High diet).

Lumbar Puncture Procedure

Participants fasted for 12 hours before the procedure. The L4-L5 space was accessed with a 24-gauge Sprott spinal needle (Sprott; Pajunk), and 30 mL of CSF was withdrawn into sterile syringes. Samples were divided into aliquots in prechilled polyethylene tubes, immediately frozen with dry ice, and stored at −70°C until assays were performed.

CSF Markers

Total levels of ApoE, Aβ40, Aβ42, and insulin were measured by enzyme-linked immunosorbent assay as previously described. The LD fractions were separated by ultracentrifugation on a potassium bromide gradient of 1.25 g/mL at 120 000 rpm for 8 hours at 4°C. The top lipid-bound fractions were removed, and the bottom LD fractions containing LD ApoE, Aβ40, and Aβ42 were measured by enzyme-linked immunosorbent assay.

Statistical Analysis

For baseline analyses, we examined differences between groups using the χ² test for categorical variables and analysis of covariance for continuous variables, with E4 status (E4+ or E4−) and memory diagnosis (normal cognition or MCI) as the class variables and levels of total Aβ or ApoE as covariates.
Apolipoprotein E Lipidation and Amyloid Peptides

Table 1. Baseline Characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline Analysis</th>
<th>Diet Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal Cognition</td>
<td>MCI</td>
</tr>
<tr>
<td></td>
<td>E4−</td>
<td>E4+</td>
</tr>
<tr>
<td>No. of participants (No. female)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15 (8)</td>
<td>5 (5)</td>
</tr>
<tr>
<td>Age, y</td>
<td>69.8 (7.6)</td>
<td>67.8 (7.0)</td>
</tr>
<tr>
<td>Education, y&lt;sup&gt;c&lt;/sup&gt;</td>
<td>14.6 (2.5)</td>
<td>14 (1.4)</td>
</tr>
<tr>
<td>Modified MMSE&lt;sup&gt;d&lt;/sup&gt;</td>
<td>96.6 (2.8)</td>
<td>98.8 (1.6)</td>
</tr>
<tr>
<td>BMI</td>
<td>28.1 (4.3)</td>
<td>26.8 (2.4)</td>
</tr>
<tr>
<td>Glucose level, mg/dL&lt;sup&gt;*&lt;/sup&gt;</td>
<td>102.2 (13.0)</td>
<td>100.2 (16.3)</td>
</tr>
<tr>
<td>Insulin level, μU/mL&lt;sup&gt;*&lt;/sup&gt;</td>
<td>14.9 (5.3)</td>
<td>13.0 (4.8)</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); E4−, negative ε4 allele status; E4+, positive ε4 allele status; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination.

* One participant (in the MCI High diet group) had an unknown E4 status.

For the intervention analysis, educational level for Low diet group with normal cognition was lower than for the High diet group with normal cognition and the Low diet group with MCI (P < .05). Age, sex, educational level, and body mass index were included as covariates (and plasma glucose and insulin levels where indicated) and were not related to the pattern of any results.

Baseline Levels of LD Aβ Peptides

Log-transformed levels of LD Aβ adjusted for total Aβ levels were analyzed with analysis of covariance by cognitive diagnosis and E4 status. A significant effect was observed for cognitive diagnosis for LD Aβ40 and LD Aβ42 levels, indicating that adults with MCI had higher LD Aβ levels than did adults with normal cognition (LD Aβ42, P = .05 [Figure 1A]; LD Aβ40, P = .01 [Figure 1B]). A trend was observed for the interaction of E4 status and cognitive diagnosis, particularly for LD Aβ40 level (LD Aβ42, P = .37; LD Aβ40, P = .11). To explore this trend, we compared least squares means, which revealed that LD Aβ42 levels were higher for E4+ adults with MCI than for E4− adults with normal cognition (P = .03 [Figure 1C]). Similarly, LD Aβ40 levels were higher for E4+ adults with MCI than for E4− adults with normal cognition and approached significance for E4+ adults with MCI (P = .06).

The fraction of the total Aβ that was LD (calculated as [LD Aβ level/total Aβ level] × 100) was also analyzed and was again higher for E4+ adults with MCI (Supplement eTable 1). For Aβ42, the percentages of LD levels for E4+ adults with MCI were higher than those of the E4− adults with MCI (P = .02) and E4− adults with normal cognition (P = .01). The fractions for the E4+ group with normal cognition (P = .06) approached statistical significance but did not achieve it. For Aβ40, the fractions of LD levels for E4+ adults with MCI were significantly higher than the percentages for the other 3 groups (P < .05).
Baseline Levels of LD ApoE

Levels of LD ApoE adjusted for total ApoE level were analyzed with analysis of covariance by cognitive diagnosis and E4 status. An overall effect for E4, but not for cognitive diagnosis, was observed; therefore, cognitive groups were combined. Levels of LD ApoE were statistically higher for E4+ compared with E4− adults (\(P < .001\)) despite having similar total levels of ApoE (mean [SEM] level, 1030 [97] ng/mL for the E4+ group vs 1112 [60] ng/mL for the E4− group; \(P = .5\)).

Next, the percentage of total ApoE that was LD was calculated (\([\text{LD ApoE level} / \text{total ApoE level}] \times 100\)) and was statistically higher for E4+ adults (56.7% [3.8%] compared with 30.2% [2.3%] for E4− adults; \(P < .001\)).

To further explore the APOE genotype interaction with LD ApoE levels, we next stratified the results by 3 APOE genotype groups. Participants in the E2 group had ε2/ε2 or ε2/ε3 genotypes (n = 7); participants in the E3 group, ε3/ε3 genotype (n = 28); and participants in the E4 group, ε3/ε4 or ε4/ε4 genotypes (n = 10). One participant with the ε2/ε4 genotype was excluded from this analysis. Figure 2B illustrates that the E4 group had the highest levels compared with the E2 and E3 group (\(P < .001\)), whereas the E2 group had the lowest levels of LD ApoE compared with the E3 group (\(P = .2\)). The same pattern was seen for the mean (SEM) fraction of LD ApoE, which was 56.9% (3.9%) for the E4 group (\(P < .001\) compared with the E2 and E3 groups), 32.3% (2.6%) for the E3 group, and 22.2% (5.1%) for the E2 group (\(P = .08\) compared with the E3 group).

Our study enrolled 1 ε4/ε4 participant (in the MCI group) whose LD ApoE proportion was 96%.

We next wanted to determine whether the depleted fractions of ApoE levels correlated with depleted fractions of β levels. Pearson product moment correlations were used to assess the relationship between LD ApoE level adjusted for total ApoE level and LD Aβ40 and Aβ42 levels adjusted for total Aβ40 and Aβ42 levels. Residuals from the adjustment calculations were used to generate the scatterplot (Figure 3). We found that LD ApoE correlated with LD Aβ40 levels (r = 0.34 [\(P = .04\)]) but not with LD Aβ42 levels (r = 0.04 [\(P = .80\)]).
Diet Effects on CSF LD Peptides

Next, we analyzed the change in CSF Aβ peptide levels in response to the diet intervention by using repeated-measures analysis of variance with cognitive diagnosis and diet treatment as class variables and change in total Aβ40 or Aβ42 level as covariates. Change scores from week 0 to week 4 were generated to display the data in graphical form (Figure 4). For LD Aβ42, the time × treatment interaction was significant, with the Low diet decreasing and the High diet increasing levels (Figure 4A; P = .01). The interaction among cognitive diagnosis × treatment × time was not significant (P = .68), indicating that similar patterns were observed for the normal cognition and MCI groups. This pattern was also seen for LD Aβ40, but the time × treatment interaction only approached significance (Figure 4B; P = .15), and the diagnosis × treatment × time effect again was not significant (P = .97).

Correlations Between Changes in LD Peptide and CSF Insulin Levels

In our previous study,27 we showed that the Low diet increased CSF insulin levels, whereas the High diet decreased them (P < .05). Pearson product moment correlations were used to analyze relationships between changes in CSF insulin and CSF LD Aβ levels. Residual change scores were constructed in which the variance due to baseline LD levels and the change in total levels were removed from week 4 LD values; thus, the residual score reflected the degree of diet-induced change in LD levels. Similar residual change scores were constructed for CSF insulin, in which the variance due to baseline levels was removed from week 4 values. For the Low diet, a higher CSF insulin level was associated with lower CSF LD Aβ levels for Aβ42 (Figure 5A; r = −0.68 [P = .01]) and for LD Aβ40 (Figure 5B; r = −0.78 [P = .002]). The correlations between the High diet changes were not significant ( LD Aβ42 and insulin levels, r = 0.04 [P = .89]; LD Aβ40 and insulin levels, r = −0.33 [P = .18]). In addition to the covariates of age, sex, educational level, and baseline body mass index, we also analyzed plasma glucose and insulin levels as covariates, and they were not related to the pattern of these results.

Discussion

Results from this pilot study suggest that adults with MCI have higher CSF LD Aβ levels, particularly if they also have E4+ status. We also show that E4+ adults have higher and E2+ adults have lower LD ApoE levels compared with E3 homozygotes. Together, these findings suggest that LD Aβ and LD ApoE are pathologic and that different APOE genotypes may modulate the risk for AD in part through alterations in ApoE lipidation. In addition, levels of LD ApoE correlate with levels of LD Aβ40. We also show that a dietary intervention modulated CSF levels of LD Aβ and that changes in LD Aβ levels inversely correlated with changes in CSF insulin levels. Therefore, altering LD fractions of Aβ may be one mechanism by which diets can increase or decrease AD risk. We have developed a hypothetical model of how APOE genotypes and diets may interact to affect binding and clearance of Aβ (Figure 6). A summary of our findings is noted in Table 2.

Lipidation States of Amyloid Peptides

Impaired clearance of Aβ40 and Aβ42 is likely an important contributor to the development of sporadic AD.1 In vitro, oligomeric Aβ peptides that are unbound to lipoproteins (LD) are toxic to synapses and neurons.6-8 Patients with AD have higher

Figure 3. Scatterplot of Lipid-Depleted β-Amyloid (LD Aβ40) Peptide Levels Log Transformed and Adjusted for Total Aβ40 Level, Compared With LD Apolipoprotein E (ApoE) Adjusted for Total ApoE Level

A, The diet with a low level of saturated fat and with a low glycemic index (Low diet) decreased lipid-depleted (LD) Aβ42 levels, whereas the diet with a high level of saturated fat and a high glycemic index (High diet) increased Aβ42 levels (P = .01). B, The Low diet decreased LD Aβ40 levels, whereas the High diet increased LD Aβ40 levels (P = .15).

Figure 4. Diet-Induced Changes (Δ) of β-Amyloid (Aβ) Peptides Log Transformed (Nat Log) and Controlled for Change in Total Aβ Levels

A, The diet with a low level of saturated fat and with a low glycemic index (Low diet) decreased lipid-depleted (LD) Aβ42 levels, whereas the diet with a high level of saturated fat and a high glycemic index (High diet) increased Aβ42 levels (P = .01). B, The Low diet decreased LD Aβ40 levels, whereas the High diet increased LD Aβ40 levels (P = .15).

Figure 4. Diet-Induced Changes (Δ) of β-Amyloid (Aβ) Peptides Log Transformed (Nat Log) and Controlled for Change in Total Aβ Levels
levels of LD Aβ in the plasma, brain parenchyma, and CSF. Our results suggest that individuals with MCI also have higher CSF Aβ levels compared with adults with normal cognition. Neuropathological samples from E4+ patients with AD show a higher amyloid plaque burden and higher synaptic oligomeric Aβ peptide levels than do samples from E4− adults, and herein we show that E4+ adults with MCI also have higher LD Aβ levels in the CSF. Although we did not directly determine whether these LD Aβ fractions are oligomers, a recent study suggests that LD Aβ fractions form oligomers in human brain tissue.

Several epidemiological studies have linked a high intake of saturated fat and simple sugar with AD risk, but the mechanisms are largely unknown. High levels of low-density lipoprotein cholesterol were associated with higher LD Aβ levels in humans, and diets high in saturated fat levels in mice led to increased delivery of plasma Aβ across the blood-brain barrier. Herein we report that a diet consisting of high levels of saturated fat and high glycemic index carbohydrates increased levels of LD Aβ and Aβ42 in the CSF, and a diet with lower levels of these macronutrients decreased the fractions. These studies suggest that diets can impart AD risk or benefit through altering the lipid environment of Aβ.

Insulin and Aβ

Diets with high levels of saturated fat can cause insulin resistance, which is a risk factor for AD. Chronic peripheral hyperinsulinemia downregulates CNS insulin, and individuals with AD have reduced brain insulin activity, evidence of brain insulin resistance, and increased oligomeric Aβ levels. Insulin may help clear brain Aβ by increasing Aβ trafficking to the plasma membrane and downregulating Aβ binding sites. Conversely, Aβ oligomers disrupt insulin signaling in animal models. Therefore, once brain insulin is disrupted, Aβ oligomer levels tend to increase, setting up a vicious cycle. We have demonstrated that the High diet that promoted peripheral insulin resistance and decreased brain insulin index (Low diet). A, Change in CSF insulin levels inversely correlated with the change in LD Aβ42 levels (P = .01). B, Change in CSF insulin levels inversely correlated with the change in LD Aβ40 levels (P = .002). MCI indicates mild cognitive impairment.

In the top panel, when ApoE is more lipidated, such as with an ε2 allele (E2+) or a healthy diet, it may be more able to bind Aβ and facilitate its clearance and degradation. When ApoE is less lipidated, such as with the E4+ state or a diet with a high level of saturated fat and a high glycemic index (High diet), it may be less able to bind Aβ. In the bottom panel, when Aβ binds to carrier proteins, such as ApoE, it is more likely to be cleared by enzymatic degradation or by crossing the blood-brain barrier (BBB). However, when Aβ is not bound to proteins, it can form oligomers that are toxic to synapses and neurons. High diets may decrease Aβ-lipoprotein binding, which will increase the toxic forms of Aβ. Conversely, diets with low levels of saturated fat and glycemic index (Low diet) may enhance Aβ-lipoprotein binding, in part by raising CNS insulin levels to optimal.

levels also increased LD Aβ levels. Furthermore, changes in CSF insulin levels inversely correlated with changes in LD Aβ levels. Many pathways disrupted by altering CNS insulin levels are also altered in E4+ individuals, including decreased Aβ clearance, synapse loss, and increases in inflammation. Our results suggest that an optimal CSF insulin state from a healthy
diet intervention or E4− status is associated with less toxic forms of CSF Aβ (Figure 6). Future studies that modulate CSF insulin with administration of intranasal insulin may be useful in clarifying the mechanisms for these findings.

**Lipidation States of Apolipoproteins**

Experimental manipulation of ApoE lipidation is emerging as a potential AD therapy. Mice treated with bexarotene, which upregulates the expression and lipidation of ApoE, demonstrated decreased levels of brain Aβ and improved scores on cognitive tasks. Work in vitro and in rodents has shown that the ApoE2 and ApoE3 isoforms are more lipidated and more efficient at binding Aβ and directing Aβ to degradation pathways. Conversely, the ApoE4 isoform is less lipidated and less able to bind and clear Aβ. Herein we provide evidence that E4+ adults have significantly less lipidated ApoE and that E2+ adults have more lipidation compared with E3 heterozygotes. We also show that levels of LD ApoE correlate with levels of LD Aβ40. These data support the theory that poorly lipidated ApoE is pathogenic. Why a similar relationship was not observed between LD ApoE and Aβ42 is unclear; future studies are needed to confirm this pattern and its possible significance.

We also show that, unlike mice that display lower levels of total ApoE when the protein is less lipidated, total ApoE is present at high levels in human CSF, which is in line with previous human studies. Thus, treatments that alter ApoE lipidation may work differently in humans, and the APOE genotype should be considered when analyzing these therapies.

**Limitations**

Owing to the intensive nature of our pilot study, the sample size was small, limiting our ability to analyze the effects of E4 status on diet response. Therefore, these data need to be replicated in a larger sample before drawing any firm conclusions. In addition, male participants were underrepresented in the E4+ group; therefore, sex effects could not be completely ruled out, although covarying for sex did not change the pattern of any result. The variability of CSF markers also limited the statistical significance of some of the findings. In addition, because of the ultracentrifuge protocol, samples underwent an additional freeze-thaw cycle before the measurement step, which may affect lipid-Aβ interactions. Baseline and 4-week samples were analyzed with this procedure, however, so how change over time would be influenced remains unclear because each participant served as his or her own control. Finally, our diet manipulated fat and carbohydrate levels; thus, we were unable to determine whether a single macronutrient class had a larger effect on Aβ lipidation.

**Conclusions**

These pilot findings suggest that E4+ individuals have significantly higher CSF LD ApoE levels than E4− individuals despite having similar total levels of ApoE and that E2+ individuals have less LD ApoE compared with other genotypes. We also show that adults with MCI have higher fractions of LD Aβ40 and Aβ42, particularly if they also have E4+ status, and that levels of LD Aβ40 correlated with LD ApoE. These preliminary data suggest that the LD fractions of ApoE and Aβ are pathogenic and that the APOE genotype should be considered when analyzing effects of AD treatments that act on lipidation.

We also demonstrate that a diet with a high level of saturated fat and a high glycemic index increases CSF LD Aβ levels, whereas a healthier diet decreases these fractions. These findings have implications not only for patients with AD but also for cognitively normal older adults who have risk factors for AD, such as E4+ status or insulin resistance. We also show that changes in LD Aβ peptide levels induced by diet moved in the opposite direction from CNS insulin levels, which may be one of the mechanisms for how diets impart AD risk or protection. Overall, these results suggest that the lipidation states of apolipoproteins and amyloid peptides might play a role in AD pathological processes and are influenced by APOE genotype and diet.

**ARTICLE INFORMATION**

Accepted for Publication: February 6, 2013.
Published Online: June 17, 2013. doi:10.1001/jamaneurol.2013.396.

Author Affiliations: Geriatric Research, Veterans Affairs Puget Sound Health Care System, University of Washington School of Medicine, Seattle (Hanson, Bayer-Carter, Green, Wilkinson, Baker, Watson, Bonner, Callaghan, Craft); Department of Pathology, University of Washington School of Medicine, Seattle (Montine); Education and Clinical Center, Department of Neurology, Veterans Affairs Puget Sound Health Care System, University of Washington School of Medicine, Seattle (Leverenz); Department of Medicine, University of Washington School of Medicine, Seattle (Hanson, Green, Tsai); Department of Psychiatry and Behavioral Science, University of Washington School of Medicine, Seattle (Bayer-Carter, Wilkinson, Baker, Watson, Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft); Department of Neurology, University of Washington School of Medicine, Seattle (Leverenz, Lampe); Fred Hutchinson Cancer Research Center, Seattle, Washington (Bonner, Postupna, Zhang, Craft).
Apolipoprotein E Lipidation and Amyloid Peptides

Original Investigation Research


